heart failure (hHF) nearly double for patients with diabetes compared to patients without diabetes. [15, 16] Further, several clinical studies have shown an increased mortality of patients with T2DM and heart failure. [7, 10, 17, 18] Clinicians, who commonly encounter patients with T2DM and heart failure in their daily practice, currently face dilemmas due to the lack of a clear consensus.
To facilitate and draw the attention of physician community toward optimal dose modification of antidiabetics for T2DM heart failure patients, a group of experts from across the India held a consensus meeting during the National Insulin Summit in Pondicherry, India, on November 8, 2015.
The objectives of the meeting were to: methodS New York Heart Association (NYHA) functional classification on heart failure was the basis for the recommendations [ Table 1 ]. [19] The expert group identified the following classes of drugs for patients with T2DM and heart failure and proposed recommendations on consensus: biguanides (metformin), sulfonylureas (SUs) (glipizide, glimepiride, glyburide, gliclazide), thiazolidinediones (pioglitazone), alpha-glucosidase inhibitors (AGIs) (acarbose, miglitol), dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin), sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin, canagliflozin, empagliflozin), glucagon-like peptide-1 receptor agonists (GLP1 RAs) (liraglutide, exenatide, dulaglutide), and various types of insulin products.
Each class of drugs was subsequently evaluated for relevant and published clinical and epidemiological evidence as well as defined place in guidelines/algorithms from national and global professional associations. These evaluations were then factored into the national context based on personal experience and common therapy practices in India. The final proposed consensus recommendations captured the collective outcome of the above process in easily implementable steps under each therapeutic drug class.
The global and national guidelines that were considered include position statement of the ADA and EASD (written henceforth as ADA-EASD position statement), AACE-ACE clinical practice guidelines (written as AACE-ACE guidelines), global guideline for type 2 diabetes, and IDF treatment algorithm for patients with type 2 diabetes (written as IDF guidelines). [20] [21] [22] [23] [24] [25] 
Glycemic targets
Glycemic goals need to be individualized, and the choice of pharmacotherapy should address challenges of hypoglycemia and weight gain.
Published scientific evidence
Optimal glycemic control has been considered to be a prime factor for combating vascular complications associated with diabetes. Indeed, studies have clearly confirmed that reducing hyperglycemia decreases the onset and progression of microvascular complications, but its effect on CV diseases (CVDs) is uncertain. [26] [27] [28] [29] However, conflicting results of the contemporary clinical trials in the recent years have produced confusion amid concerns that tight glycemic control, in some circumstances, could even be unfavorable. The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) and Veterans Affairs Diabetes Trial studies found no effect of intensive glucose control on major cardiovascular events (MACEs). [30, 31] Moreover, the Action to Control Cardiovascular Disease in Diabetes (ACCORD) study recognized an increased risk for death from CV causes and total mortality with intensive glucose control. [32] In this context, a meta-analysis reported that intensive glycemic control reduced the risk for CVDs (relative risk [RR], 0.90; 95% confidence interval [CI], 0.83-0.98) but did not reduce the risk for all-cause mortality (RR, 0.98; 95% CI, 0.84-1.15), CV mortality (RR, 0.97; 95% CI, 0.76-1.24), or stroke (RR, 0.98, 95% CI, 0.86-1.11). [33] Another meta-analysis reported that intensive glycemic control reduced the risk for major CVD (hazard ratio [HR], 0.91; 95% CI, 0.84-0.99), 16 ). [34] Furthermore, the relationship between glycated hemoglobin (HbA1c) and consequences seems more complex in patients with T2DM and heart failure. Some studies demonstrated a probable "U-shaped" or an inverse relationship between HbA1c and mortality. [35] [36] [37] In a study of 5815 ambulatory heart failure patients receiving medical treatment for diabetes, individuals with modest glycemic control (HbA1c >7.1%-7.8%) had lower mortality compared with HbA1c levels that were either higher or lower. [36] Conversely, a meta-analysis indicated that intensive glycemic (HbA1c level below 7.0%) control has CV benefits and does not increase all-cause mortality. [38] In addition, in 2412 participants (of which 907 participants had known diabetes) enrolled in Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity study, increasing levels of HbA1c was associated with increased risk of total mortality, hHF, and a composite outcome of CV death or hHF. [38] In the view of these findings, further studies are warranted before a conclusion can be drawn on the impact of intensive glycemic control in patients with diabetes and heart failure. [38, 39] Current place in guidelines/recommendations ADA recommends less stringent HbA1c goals (such as < 8% [64 mmol/mol]) for patients with advanced microvascular or macrovascular complications. [40] AACE/ American College of Endocrinology guidelines recommends that HbA1c target should be individualized based on numerous factors, such as age, life expectancy, comorbid conditions, duration of diabetes, and risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation, and adherence. [25] Further, an HbA1C ≤6.5% is considered optimal if it can be achieved in a safe and affordable manner, but higher targets may be appropriate for certain individuals and may change for a given individual over time. [25] Similarly, ADA-EASD position statement recommends for personalization of the treatment, while balancing the benefits of glycemic control with its potential risks, taking into account the adverse effects of glucose-lowering medications (particularly hypoglycemia), the patient's age and health status, among other concerns. [24] Oral antidiabetic agents
Biguanides: Metformin
Metformin may be used in low doses. It may lead to lactic acidosis in unstable or acute congestive heart failure who are at risk of hypoperfusion and hypoxemia [ Table 2 ].
Published scientific evidence
Formally, metformin was contraindicated in patients with heart failure as it causes lactic acidosis. [41, 42] However, a recent systematic review of observational studies witnessed that metformin compared to control group is associated with lower rate of all-cause mortality (23% vs. 37%, pooled adjusted risk estimates 0.80, 0.74-0.87, I 2 = 15%, P < 0.001) and all-cause hospitalizations (35% vs. 64%, pooled adjusted risk estimate 0.93, 0.89-0.98, I 2 = 0%, P = 0.01) in patients with T2DM and heart failure. Metformin did not increase the risk of lactic acidosis in the patients with reduced LV ejection fraction and patients with heart failure and chronic kidney disease. [43] Thus, the review concluded that metformin can be considered for the treatment of patients with T2DM and heart failure. [43] Further, a study which compared heart failure patients with or without metformin therapy reported that metformin was associated with lower mortality (HR 0.85; 95% CI, 0.82-0.88), mostly due to a less CV death (HR 0.78; 0.74-0.82), and with decreased hospitalization rate (HR 0.81; 0.79-0.84). [44] Moreover, a cohort study reported that metformin alone or combination with SU was associated with fewer deaths compared to the SU monotherapy at 1 year (HR 0.59; 95% CI, 0.36-0.96) and over long-term follow-up (HR 0.67; 95% CI, 0.51-0.88) in chronic heart failure (CHF) patients. [45] Further, a couple of recent observational studies also suggested that metformin can be a safe and effective alternative drug for the management of diabetes with concomitant heart failure. [46, 47] Current place in guidelines/recommendations ADA recommends use of metformin in stable CHF patients with the absence of renal impairment and restricts its usage in unstable and hospitalized patients. [40] The European Society of Cardiology (ESC) guidelines recommends metformin in patients with heart failure without other comorbidities such as liver or renal dysfunction. [48] The Australian Diabetes Society does not recommend metformin in patients with severe cardiac failure. [49] IDF does not recommend metformin in elderly patients with CHF. Similarly, Indian Council of Medical Research (ICMR) also does not recommend metformin in patients with CHF. [50] The consensus by an independent group from Germany recommends metformin in NYHA class I and II heart failure but not in NYHA class III or IV. [51] Prescribing information
Prescribing information of metformin does not recommend use in patients with congestive heart failure requiring pharmacologic management, in particular those with unstable or acute congestive heart failure. Moreover, caution should be taken while using metformin in the patients with acute congestive heart failure. [52] 
Sulfonylureas
SUs should be considered only if metformin is contraindicated or when given in combination with metformin [ Table 3 ].
Published scientific evidence
To achieve optimal glycemic targets, SUs have emerged as alternative treatment options to metformin. [53] Currently, there is a paucity of data with regard to the use of SU in patients with T2DM and heart failure. A retrospective cohort study compared SU against metformin in 12,272 diabetic patients and CHF. Over 2.5 years of follow-up, SU monotherapy was associated with higher mortality (52% vs. 33%) and hospitalizations (70% vs. 69%) compared to metformin monotherapy. [54] Further, a systematic review and meta-analysis reported a higher risk of heart failure with SUs compared to metformin (RR 1.17, 95% CI, 1.06-1.29, I 2 = 24%). [55] An observational study compared the long-term mortality of SUs in patients with diabetes and CHF. The study found similar HR for mortality with glimepiride (1.10, 95% CI, 0.92-1.33), glibenclamide (1.12, 0.93-1.34), and glipizide (1.14 [0.93-1.38]). [56] In addition, a dose-response analysis concluded that high-dose SU (median daily dose of >4 mg for glyburide) was associated with more episodes of heart failure than high-dose metformin (adjusted HR 1.24; 95% CI, 1.01-1.54) and low-dose SU (HR 1.38; 95% CI, 1.20-1.60). The study concludes that physicians should carefully weigh benefits versus risks while prescribing high-dose SUs in diabetic patients with CHF. [57] Gliclazide has been suggested as a better SU agent for patients with T2DM and CV risk. Indeed, the ADVANCE study found that rigorous glucose control with gliclazide has no significant effect on major macrovascular events. [30, 58] In addition, recent studies have documented lower risk of CV events and mortality with gliclazide. [59, 60] In contrast, another study found that metformin demonstrated its superiority over gliclazide in terms of CV safety. [61] Current place in guidelines/recommendations
No specific guidelines are available pertaining to SU.
Prescribing information
The prescribing information of glipizide, glimepiride, and glyburide mentions that there is an increased risk of CV mortality with SU. Therefore, these agents may be avoided in patients with CV risk. [62] [63] [64] Thiazolidinediones Pioglitazone is contraindicated in patients with symptomatic heart failure New York Heart Association Class III or IV. Caution is also advised while their use in patients with New York Heart Association Class I or II heart failure [ Table 4 ].
Published scientific evidence
The peroxisome proliferator-activated receptor-γ-activating thiazolidinediones are known to cause sodium retention and plasma volume expansion. [65, 66] Fluid retention may aggravate heart failure and lead to increased number of hospitalizations. [66, 67] The PROactive trial compared pioglitazone against placebo in T2DM patients with preexisting CVDs. The study reported more cases of serious heart failure with pioglitazone (5.7%) than the placebo group (4.1%) (P = 0.007). However, death due to heart failure was comparable for pioglitazone (0.96%) and placebo (0.84%) (P = 0.639). [68] Further, a double-blind randomized controlled trial (RCT) compared pioglitazone with glyburide in NYHA functional class I heart failure patients. Pioglitazone was associated with more incidence of heart failure (10 vs. 7 patients), edema (21.2% vs. 12.8%), and weight gain (2.565 vs. 0.864 kg) as compared to glyburide. [69] Similarly, another RCT examined the safety of pioglitazone and glyburide with or without insulin in NYHA Class II and III heart failure patients. The study reported that pioglitazone as compared to glyburide was associated with a higher incidence of heart failure (30 vs. 15 patients). [70] A systematic review and meta-analysis compared pioglitazone with other oral hypoglycemic agents in patients with T2DM. Pioglitazone reported higher risk of heart failure as compared to metformin (RR: 1.14; 95% CI, 0.86-1.50) and SU (RR: 1.30; 95% CI, 0.90-1.87). [55] Current place in guidelines/recommendations
Several guidelines restrict use of thiazolidinediones in patients with diabetes and heart failure. The ADA guidelines recommend restricting the usage of thiazolidinediones in symptomatic CHF patients. [40] Similarly, European Society of Cardiology (ESC) comments that thiazolidinediones should not to be used in T2DM with heart failure patients since water retention may deteriorate or aggravate heart failure. [71] ICMR guidelines also recommend to avoid thiazolidinediones in patients with a history of CHF. [50] Consensus by an independent group from Germany recommend to not use pioglitazone in all NYHA class of heart failure as it elevates cardiac decompensation. [51] Prescribing information Pioglitazone prescribing information recommends avoiding its use in patients with symptomatic heart failure and in patients with NYHA Class III or IV heart failure. [72] 
Alpha-glucosidase inhibitors
There is limited data available with AGIs that examine their beneficial and/or harmful effects in patients with diabetes and heart failure. Thus, we recommend its use with caution [ Table 5 ].
Published scientific evidence
AGIs have emerged as an alternative first-line therapy in old-aged DM patients due to low risk of hypoglycemia and better postprandial glycemic control. [53] A few studies have examined the CV safety of AGIs. For instance, acarbose in an RCT, Study to Prevent Non-insulin Dependent Diabetes Mellitus displayed a 34% RR reduction (RRR) of hypertension and a 49% RRR of CV events, as well as a 36% RRR of developing T2DM in patients with impaired tolerance to glucose. [73, 74] A meta-analysis demonstrated that acarbose reduced CV events in patients with T2DM (HR 0.65; 95% CI, 0.48-0.88, P = 0.0061). [75] The gluco VIP trial, a multinational, observational study investigated the efficacy, safety, and tolerability of acarbose as add-on or monotherapy in a large cohort of Asian patients with or without CV morbidities. The results indicate that acarbose was effective and safe with a good tolerability profile regardless of the presence of CV comorbidities or diabetes-related complications. [76] However, an intension-to-treat cohort study reported that acarbose was associated with higher risk of CV events (HR 1.05; 95% CI, 1.01-1.09), heart failure (HR 1.08; 95% CI, 1.00-1.16), and ischemic stroke (HR 1.05; 95% CI, 1.00-1.10) compared to metformin as first-line therapy in T2DM. [77] So far, the data are limited and further studies are warranted. The Acarbose Cardiovascular Evaluation (ACE) trial is underway involving patients with impaired glucose tolerance and established coronary heart disease. The trial examines the impact of acarbose on CV-related morbidity and mortality. [78] 
Current place in guidelines/recommendations
There are no guidelines specific to use of AGIs in patients with heart failure.
Prescribing information
The prescribing information of acarbose did not comment on use in patients with CHF.
Dipeptidyl peptidase-4 inhibitors
Data with DPP4 inhibitors in New York Heart Association Class III-IV is still limited. We recommend its use with caution.
Published scientific evidence
Dipeptidyl-peptidase-4 inhibitors are considered as a second-line therapy after metformin in the treatment of T2DM. [79] Several studies have been conducted to establish the CV safety of DPP-4 inhibitors. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) examined and confirmed the noninferiority of sitagliptin compared to placebo, in terms of primary composite CV outcome (HR, 0.98; 95% CI, 0.88-1.09; P < 0.001) and hHF (HR, 1.00; 95% CI, 0.83-1.20; P = 0.98). [80] In addition, the trial showed no difference in total hHF between the sitagliptin and placebo groups (unadjusted HR, 1.00; 95% CI, 0.80-1.25). Rates of CV death (22.4% vs. 23.1%) and post-hHF all-cause death (29.8% vs. 28.8%) were also similar between groups. [80] Therefore, the TECOS study concludes that sitagliptin may be used safely in patients with T2DM at high CV risk. [81] The EXAMINE study evaluated alogliptin (25, 12.5, and 6.25 mg QD dose) compared to placebo for CV safety over a median follow-up period of 1.5 years. The study reported more hHF in the alogliptin group compared to placebo (3.1 vs. 2.9%, HR, 1.07; 95% CI, 0.79-1.46) within the composite endpoint. In addition, alogliptin did not induce new onset of heart failure and did not worsen heart failure outcomes in patients with a history of heart failure. [82] Subsequent reports from the EXAMINE study indicate that alogliptin in patients with type 2 diabetes and recent acute coronary syndromes does not show any effect on composite events of CV death and hHF in the post hoc analysis (HR, 1.00; 95% CI, 0.82-1.21). [83] Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (TIMI) 53 trial was conducted in diabetic patients with existing CVDs comparing saxagliptin (5 mg/day) versus standard of care. The study reported higher rate of hHF (3.5% vs. 2.8%, HR, 1.27; 95% CI, 1.07-1.51; P = 0.007) in saxagliptin group compared to placebo group. [84] Subsequent reports reported 27% higher RR of hHF with saxagliptin [ Table 6 ]. In addition, the increased hHF was highest among the patients with elevated levels of natriuretic peptides, prior heart failure, or chronic kidney disease [ Table 7 ]. [85] The Vildagliptin in Ventricular Dysfunction Diabetes trial included patients with NYHA Class I to III heart failure. The trial reported more CV deaths in the treatment arm than in the placebo arm. [86] In addition, there was a statistically considerable increase in LV end-diastolic volume and a propensity toward increased LV end-systolic volume within the vildagliptin arm. [86] A comprehensive patient-level pooled analysis of 19 double-blinded RCTs of linagliptin versus placebo in patients with T2DM reported all-cause mortality (13 vs. 11 patients; HR, 0.81; 95% CI, 0.36-1.81) and hospitalization for CHF (12 vs. 9 events; HR, 1.04; 95% CI, 0.43-2.47). The study concluded that linagliptin is not associated with increased CV risk versus active comparators (glimepiride and voglibose) or placebo. [87] The Cardiovascular and Renal Microvascular Outcome Study with linagliptin trial is presently ongoing. [88] 
Current place in guidelines/recommendations
There are no specific guidelines pertaining to the use of DPP-4 inhibitors in patients with heart failure.
Prescribing information
Prescribing information recommend to evaluate risks and benefits of saxagliptin before initiating treatment in patients at a higher risk for heart failure [89] and to avoid vildagliptin in patients with NYHA functional class IV heart failure. [90] 
Sodium glucose cotransporter-2 inhibitors
There are limited data available with SGLT2 inhibitors in heart failure. They may be useful due to their mild diuretic effect. We recommend using SGLT2 inhibitors cautiously.
Published scientific evidence SGLT2 inhibitor could be an attractive drug for patients with T2DM and chronic Heart Failure with Reduced Ejection Fraction as a part of the SGLT2 inhibitor mechanism includes diuresis, which leads to a preload reduction. At present, canagliflozin, dapagliflozin, and empagliflozin are the three SGLT2 inhibitors approved for the treatment of T2DM by the US Food and Drug Administration and European Medicines Agency. [91] [92] [93] [94] A systematic review and meta-analysis of RCTs [95] A recent meta-analysis compared dapagliflozin (2.5-10 mg) with control in T2DM patients. Dapagliflozin reported CV beneficial effect for both overall population (HR 0.77; 95% CI, 0.54, 1.10 for MACE) and in patients with a history of CVD (HR 0.80; 0.53, 1.22). In addition, hHF with dapagliflozin was lower compared to control (event rate/100 patient years 0.15 vs. 0.41, HR 0.361; 95% CI, 0.156-0.838). [96] The CV effects of dapagliflozin are being tested in the ongoing DECLARE-TIMI58 study. [97] The EMPA-REG outcome trial evaluated empagliflozin (10 or 25 mg OD) in high-risk CVD patients for a median duration of 3.1 years [ Table 8 ]. Empagliflozin compared to placebo group reported 38% and 35% RRR for CV death (3.7 vs. 5.9%, HR 0.62; 95% CI, 0.49-0.77, P < 0.001) and hHF (2.7 vs. 4.1%, HR 0.65; 95% CI, 0.50-0.85, P = 0.002), respectively. In addition, empagliflozin was also associated with 32% RRR of death from all causes than placebo. [98] Recent reports from the trial show that empagliflozin reduced hHF and CV death in all patients irrespective of history of heart failure. [99] This response could be due to inhibition of renal sodium and glucose reabsorption.
Canagliflozin proved its safety and efficacy in a wide range of patients with T2DM, [100, 101] but CV effects still remain uncertain. At present, according to the interim analysis of the CANagliflozin cardioVascular Assessment Study (CANVAS) study, canagliflozin may not increase the overall CV risk. [102] The ongoing CANDLE trial in patients with T2DM and CHF (NYHA I-III class) evaluates the clinical safety and efficacy of canagliflozin. [103] In addition, the Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy, [104] CANVAS, [105] effects of Canagliflozin on Renal Endpoints (CANVAS-R) [106] and Cardiovascular Outcomes Trial [107] are presently ongoing.
Current place in guidelines/recommendations
Canadian guidelines recommend adding an SGLT2 inhibitor to the antihyperglycemic therapy in patients with uncontrolled hyperglycemia and a history of CVD. [108] Prescribing information
The prescribing information of SGLT2 inhibitors does not comment on use in patients with CHF.
Injectable antidiabetic agents
Glucagon-like peptide-1 receptor agonists GLP1 RAs should be used with caution while managing patients with New York Heart Association Class I-II heart failure. No evidence is available with New York Heart Association Class III-IV.
Published scientific evidence GLP1 RAs seems to have positive effects on the CV system. [109] [110] [111] [112] A meta-analysis of RCTs, which assessed MACE, mortality, and CV risk factors, found that of GLP1 RAs were associated with a substantial drop in the incidence of MACEs, compared with placebo and pioglitazone, and a similar effect as active comparators (SU, insulin, and DPP-4 inhibitors). [113] In addition, a large meta-analysis of 32 trials observed a greater reduction in systolic blood pressure (SBP) by GLP1 RAs in comparison to other active antiglycemic comparators. [114] A large cohort study reported that the rate of hHF did not increase with the use of incretin-based drugs (GLP1 RAs) as compared with oral antidiabetic drug combinations among patients with a history of heart failure (HR, 0.86; 95% CI, 0.62-1. 19) or among those without a history of heart failure (HR, 0.82; 95% CI, 0.67-1.00). [115] A retrospective study of patients undergoing treatment for T2DM witnessed that exenatide showed a lower risk of CV events and hospitalizations (CVD-related and all-cause) than treatment with other glucose-lowering treatments, including metformin, AGIs, thiazolidinediones, SU, DPP-4 inhibitors, and insulin [ Table 9 ]. [116] The LEADER trial investigated effect of liraglutide (1.2 and 1.8 mg) in patients with T2DM and CV risk. It demonstrated a statistically significant reduction in CV risk (CV death, nonfatal myocardial infarction, or nonfatal stroke). [117] A study evaluating dulaglutide in patients with T2DM on three or fewer medications for hypertension demonstrated that dulaglutide 1.5 mg resulted in significantly lower SBP (95% CI, −2.8 mmHg [−4.6, −1.0]; P ≤ 0.001) compared to placebo. [118] The 0.75-mg dose was shown to be noninferior to placebo. [118] In addition, the Researching Cardiovascular Events With a Weekly Incretin in Diabetes study is presently ongoing [ Table 9 ]. [119] The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) study was conducted to establish the CV safety of lixisenatide. [120] The findings of ELIXA study showed no increased risk for the primary composite endpoint, lixisenatide versus placebo: 13.4% versus 13.2% (HR, 1.02; 95% CI, 0.89-1.17). [120] There was no significant difference in the rate of hHF lixisenatide versus placebo: 4.0% versus 4.2% (HR, 0.96; 95% CI, 0.75-1.23) and rate of death (HR. 0.94; 95% CI, 0.78-1.13) between the groups [ Table 10 ]. [120] Exenatide Study of Cardiovascular Event Lowering trial [121] and effects of Liraglutide in Young Adults with Type 2 DIAbetes [122] are the ongoing trials assessing the CV safety of exenatide and liraglutide, respectively.
Current place in guidelines/recommendations
There are no guidelines specific to use of GLP1 RAs in patients with heart failure.
Prescribing information
The prescribing information of GLP1 RAs did not comment on use in patients with heart failure.
Dose modification with insulins
Insulin dose should be titrated to requirements to reduce the risk of hypoglycemia.
Insulin analogs may be preferred agents in patients at risk for hypoglycemia.
Published scientific evidence
Insulin is known to contribute to arterial dilatation in skeletal muscle and is thus expected to be an attractive agent in achieving ideal glycemic control in CV patients. [123] Insulin is a selective skeletal muscle vasodilator that leads to increased muscle perfusion primarily through redistribution of regional blood flow. [124] [125] [126] Several studies have demonstrated the CV safety of insulins. The Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) and DIGAMI 2 studies in patients with diabetes mellitus and acute myocardial infarction showed no increase in rates of heart failure in insulin-treated groups. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial did not find adverse effects with insulin glargine treatment in patients with T2DM and heart failure, with CV risk factors. [127] The long-term (>6 years) follow-up of the ORIGIN study documented neutral effects of insulin glargine on CV outcomes. [128] Further, the data analyses of a recent study ACCORD showed no association of insulin with the CV mortality. [129] Recently, an RCT in patients with T2DM and diastolic dysfunction found that the insulin analogs (insulin detemir, insulin aspart, and NPH-insulin) treatment was associated with improved diastolic cardiac function, compared to human insulin. [130] An ongoing trial comparing CV safety of insulin Degludec Versus insulin glargine in subjects with Type 2 Diabetes at high risk of cardiovascular Events (DEVOTE) will give further insights on use of insulin analogs in patients who are at high risk of CV events [ Table 11 ]. [131] Current place in guidelines/recommendations Indian National Consensus Group recommends use with caution and a swift clinical action is recommended if any deterioration in cardiac symptoms occur. [21] Prescribing information
Prescribing information of insulin glargine, insulin glulisine, insulin aspart 30/70, insulin degludec, and IDegAsp recommends dosage reduction or discontinuation of thiazolidinediones during concomitant use of insulins should be considered if signs and symptoms of heart failure occur [ Table 11 ]. [132] [133] [134] [135] [136] concluSIon Patients with T2DM are prone to develop CV comorbidities.
Patients with diabetes and heart failure pose a challenge while managing glycemic control. Most of the agents discussed in the present consensus statement do lack CV safety data. Metformin is relatively safe in treating patients with T2DM and heart failure. SUs such as glipizide, glimepiride, glibenclamide and glyburide share a similar kind of low CV safety profile.
Gliclazide has been found to be a safe drug among SU. Thiazolidinediones have been found to be associated with fluid retention. The CV safety profile of AGIs is also not clear due to lack of evidence. Among DPP-4 inhibitors, sitagliptin, saxagliptin and alogliptin have been evaluated for CV safety. Saxagliptin has been associated with a higher rate of hHF. Currently, CV safety of GLP1 RAs has been examined in several clinical studies; some of them are showing impressive CV safety. Recent evidence with SGLT2 inhibitors provides reassuring signals. The safety data with insulins in patients with T2DM and heart failure are evolving. Some studies have shown good CV effects with insulin analogs. Considering all this evidence, existing guidelines from various professional bodies, and personal experiences in clinics, we have formulated the present consensus statement.
This consensus has been developed with due considerations to the Indian population. The consensus was aimed at providing simple and practical recommendations on the use of antidiabetic agents in patients with T2DM and heart failure. However, the present consensus statement suffers from lack of published and robust evidence from studies among local people. This may appear surprising given the huge burden of T2DM in India. We are aware that clinical and epidemiological research in India is resource-intensive in terms of economic expenses and other resources. It is promising that some organizations have started to invest in such epidemiological studies. [137] We believe that present consensus recommendations on antidiabetic drugs for patients with T2DM and heart failure will be a beneficial tool for physicians and their effect will be corroborated through observational studies in daily clinical practice.
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